Companies › 1ST Biotherapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Neurology, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FB418 | – | Phase 1 | Parkinson Disease Psychosis | – |
| FB849 | – | Phase 1 | Advanced Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05995782 | FB418 | Phase 1 | Parkinson Disease Psychosis | Neurology | Dec 2024 |
| NCT05761223 | FB849 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.